Kanada - Ingliż - Health Canada

pfizer canada ulc - coagulation factor ix (recombinant) - powder for solution - 250unit - coagulation factor ix (recombinant) 250unit - hemostatics

Kanada - Ingliż - Health Canada

pfizer canada ulc - coagulation factor ix (recombinant) - powder for solution - 500unit - coagulation factor ix (recombinant) 500unit - hemostatics

Kanada - Ingliż - Health Canada

pfizer canada ulc - coagulation factor ix (recombinant) - powder for solution - 1000unit - coagulation factor ix (recombinant) 1000unit - hemostatics

Kanada - Ingliż - Health Canada

pfizer canada ulc - coagulation factor ix (recombinant) - powder for solution - 2000unit - coagulation factor ix (recombinant) 2000unit - hemostatics

Kanada - Ingliż - Health Canada

pfizer canada ulc - coagulation factor ix (recombinant) - powder for solution - 1500unit - coagulation factor ix (recombinant) 1500unit - hemostatics

Kanada - Ingliż - Health Canada

pfizer canada ulc - coagulation factor ix (recombinant) - powder for solution - 3000unit - coagulation factor ix (recombinant) 3000unit - hemostatics

Stati Uniti - Ingliż - NLM (National Library of Medicine)

wyeth biopharma division of wyeth pharmaceuticals llc - coagulation factor ix recombinant human (unii: 382l14738l) (coagulation factor ix recombinant human - unii:382l14738l) - coagulation factor ix recombinant human 1000 [iu] in 5 ml - benefix® , coagulation factor ix (recombinant), is a human blood coagulation factor indicated in adults and children with hemophilia b (congenital factor ix deficiency or christmas disease) for: limitation of use benefix is not indicated for induction of immune tolerance in patients with hemophilia b [see warnings and precautions (5.3)] . benefix is contraindicated in patients who have manifested life-threatening, immediate hypersensitivity reactions, including anaphylaxis, to the product or its components, including hamster protein. risk summary there are no data with benefix use in pregnant women to inform a drug-associated risk. animal reproduction studies have not been conducted with benefix. it is not known whether benefix can affect reproductive capacity or cause fetal harm when given to pregnant women. in the u.s. general population, the estimated background risk of major birth defect and miscarriage in clinically recognized pregnancies is 2–4% and 15–20%, respectively. risk summary there is no informa

Għarabja Sawdita - Ingliż - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

wyeth, spain - coagulation factor ix recombinant human - powder and solvent for solution for injection - 1000 iu

Għarabja Sawdita - Ingliż - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

wyeth, spain - coagulation factor ix recombinant human - powder and solvent for solution for injection - 250 iu

Għarabja Sawdita - Ingliż - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

wyeth, spain - coagulation factor ix recombinant human - powder and solvent for solution for injection - 500 iu